1. Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatmentBarbara Šenk, Katja Goričar, Viljem Kovač, Vita Dolžan, Alenka Franko, 2019, izvirni znanstveni članek Ključne besede: malignant mesothelioma, genetic polymorphism, cisplatin, biomarkers Objavljeno v DiRROS: 05.07.2024; Ogledov: 137; Prenosov: 35 Celotno besedilo (331,53 KB) |
2. |
3. The influence of genetic variability on the risk of developing malignant mesotheliomaAlenka Franko, Nika Kotnik, Katja Goričar, Viljem Kovač, Metoda Dodič-Fikfak, Vita Dolžan, 2018, izvirni znanstveni članek Ključne besede: malignant mesothelioma, genetic polymorphism, antioxidative enzymes, genetic variability Objavljeno v DiRROS: 10.06.2024; Ogledov: 174; Prenosov: 68 Celotno besedilo (1,13 MB) |
4. Association between SLC19A1 gene polymorphism and high dose methotrexate toxicity in childhood acute lymphoblastic leukaemia and non Hodgkin malignant lymphoma : introducing a haplotype based approachBarbara Faganel Kotnik, Janez Jazbec, Petra Bohanec Grabar, Christina Rodriguez-Antona, Vita Dolžan, 2017, izvirni znanstveni članek Ključne besede: acute lymphoblastic leukaemia, genetic polymorphism, haplotype, methotrexate Objavljeno v DiRROS: 31.05.2024; Ogledov: 202; Prenosov: 163 Celotno besedilo (647,20 KB) Gradivo ima več datotek! Več... |
5. Antioxidant defence-related genetic variants are not associated with higher risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescenceAna Lina Vodušek, Katja Goričar, Barbara Gazić, Vita Dolžan, Janez Jazbec, 2016, izvirni znanstveni članek Povzetek: Background. Thyroid cancer is one of the most common secondary cancers after treatment of malignancy in childhood or adolescence. Thyroid gland is very sensitive to the carcinogenic effect of ionizing radiation, especially in children. Imbalance between pro- and anti-oxidant factors may play a role in thyroid carcinogenesis. Our study aimed to assess the relationship between genetic variability of antioxidant defence-related genes and the risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescence. Patients and methods. In a retrospective study, we compared patients with childhood or adolescence primary malignancy between 1960 and 2006 that developed a secondary thyroid cancer (cases) with patients (controls), with the same primary malignancy but did not develop any secondary cancer. They were matched for age, gender, primary diagnosis and treatment (especially radiotherapy) of primary malignancy. They were all genotyped for SOD2 p.Ala16Val, CAT c.-262C>T, GPX1 p.Pro200Leu, GSTP1 p.Ile105Val, GSTP1 p.Ala114Val and GSTM1 and GSTT1 deletions. The influence of polymorphisms on occurrence of secondary cancer was examined by McNemar test and Cox proportional hazards model. Results. Between 1960 and 2006 a total of 2641 patients were diagnosed with primary malignancy before the age of 21 years in Slovenia. Among them 155 developed a secondary cancer, 28 of which were secondary thyroid cancers. No significant differences in the genotype frequency distribution were observed between cases and controls. Additionally we observed no significant influence of investigated polymorphisms on time to the development of secondary thyroid cancer. Conclusions. We observed no association of polymorphisms in antioxidant genes with the risk for secondary thyroid cancer after treatment of malignancy in childhood or adolescence. However, thyroid cancer is one of the most common secondary cancers in patients treated for malignancy in childhood or adolescence and the lifelong follow up of these patients is of utmost importance. Ključne besede: secondary thyroid cancer, antioxidant genes, genetic polymorphism Objavljeno v DiRROS: 09.05.2024; Ogledov: 251; Prenosov: 176 Celotno besedilo (500,53 KB) Gradivo ima več datotek! Več... |
6. GLCCI1 polymorphism rs37973 and asthma treatment response to inhaled corticosteroidsMatija Rijavec, Mateja Žavbi, Anton Lopert, Matjaž Fležar, Peter Korošec, 2018, izvirni znanstveni članek Povzetek: Background. Asthma treatment response is highly variable and pharmacogenetic markers that predict treatment response would be one step closer to personalized treatment. GWAS studies have shown that polymorphisms GLCCI1 could be associated with asthma treatment response to inhaled corticosteroids (ICS). Materials and methods. We genotyped rs37973 of GLCCI1 in 208 adult asthma patients treated with ICS. Change in % predicted FEV1 was analysed after short-term (3 months) and after long-term (at least 3 years) treatment. Treatment success was defined as good when FEV1 decreased less than 30 ml/year. Results. After 3 months of treatment, change of % predicted FEV1 was higher in patients with GG genotype than in patients with AG+AA genotype, and this genotype dependent difference was only evident in non-smokers. Similar results were found after at least 3 years of treatment when all patients were analysed, in non-smokers and patients with atopy. Even though, no differences in treatment success (good vs. poor response) were observed when analysing the entire group of patients, genotype dependent treatment success was highly influenced by smoking and atopy. GG genotype was overrepresented in non-smokers and patients with atopy with good response. Conclusions. Rs37973 was associated with short- and long-term treatment response; however, there was a great influence of smoking and atopy on pharmacogenetic association. Furthermore, we found GG genotype to be associated with better treatment response, what is contrary to results found in GWAS. Ključne besede: asthma -- diagnosis -- therapy, pharmacogenetics, genetic polymorphism, smoking, inhaled corticosteroids, atopy, GLCCI1, FEV1, rs37973 Objavljeno v DiRROS: 16.12.2020; Ogledov: 1623; Prenosov: 431 Povezava na datoteko |
7. Gene - nutrition interaction and plant metabolites in the treatment of human hereditary based disordersIvan Kreft, Sayoko Ikeda, Kiyokazu Ikeda, Vida Škrabanja, Giovanni Bonafaccia, 1997, objavljeni znanstveni prispevek na konferenci (vabljeno predavanje) Ključne besede: genetic polymorphism, allergies, carcinogenesis, cardio-vascular diseases, errors of metabolism Objavljeno v DiRROS: 12.07.2017; Ogledov: 2875; Prenosov: 789 Celotno besedilo (122,11 KB) |